Figure 3 — The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma

Research Paper|Volume 16, Issue 5|pp. 4378–4395

The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma

Back to articleFigure 3(3 of 8)

100%

Figure 3.Validation of the SUMOPS model to predict the prognosis of LUAD patients. (A–E) Prognostic analysis investigating the role of SUMOPS in predicting outcomes within the (A) GSE11969, (B) GSE13213, (C) GSE26939, (D) GSE68465, and (E) GSE72094 cohort. (F) The meta-analysis indicated that the LUAD patients with high SUMOPS suffered poorer overall survival.